Pharmaceutical Executive
How navigating compliance risks requires so much more than policies and procedures.
Kevin J. Slatkavitz
Advertisement
Articles by Kevin J. Slatkavitz
Advertisement
Latest Updated Articles
A Seat at the Strategy TableJuly 8th 2018
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
4
Evidence With Purpose: Making Real-World Research Better, Not Just Faster
5